Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis

2021 ◽  
Author(s):  
Delamo I. Bekele ◽  
Elizabeth Cheng ◽  
Andreas Reimold ◽  
Christian Geier ◽  
Kavya Ganuthula ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Axial Spondyloarthritis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Factor Inhibitor ◽  
Male Cohort ◽  
Necrosis Factor

Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis

2018 ◽  
Vol 70 (9) ◽  
pp. 1393-1399 ◽  
Author(s):  
Mansour Alazmi ◽  
Ismail Sari ◽  
Bharath Krishnan ◽  
Robert D. Inman ◽  
Nigil Haroon
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Axial Spondyloarthritis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Factor Inhibitor ◽  
Necrosis Factor ◽  
Inhibitor Treatment

scholarly journals Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

2021 ◽  
Author(s):  
David L Kaplan ◽  
Brian L Ung ◽  
Corey Pelletier ◽  
Chuka Udeze ◽  
Ibrahim Khilfeh ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Claims Data ◽  
Tumor Necrosis Factor Inhibitor ◽  
Total Cost ◽  
Factor Inhibitor ◽  
Treatment Data ◽  
Necrosis Factor

Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

Sign in / Sign up

Export Citation Format

Share Document